3 October 2019

AMRA Announces Two Abstracts Accepted for Presentation at AASLD 2019 Liver Meeting in Boston

AMRA Announces Two Abstracts Accepted for Presentation at AASLD 2019 Liver Meeting in Boston

LINKÖPING, Sweden; October 3, 2019 –  AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease.

Two abstracts highlighting the power of AMRA’s technology have been accepted by AASLD for presentation at The Liver Meeting® 2019 in Boston, Massachusetts. AMRA will present key insights and findings on the utility of MRI-based muscle composition assessments on patients with non-alcoholic fatty liver disease (NAFLD) using data from the large UK Biobank Imaging Study.

Sarcopenia is a common complication among those with cirrhosis and end-stage liver disease and may be predictive of comorbidities and prognosis, however, a consistent and objective definition is lacking. AMRA’s technology was used to assess muscle composition in participants with NAFLD to assess its potential for developing a standardized clinical definition of sarcopenia and for tracking and predicting disease progression.

In a study of 9 615 participants, AMRA revealed higher clinical relevance of assessing the deviation from expected muscle volume rather than measuring muscle volume directly. Combining deviation from muscle volume and muscle fat infiltration assessment provides a more exhaustive, muscle-specific description linked to function enabling objective evaluation of sarcopenia-related problems within NAFLD.

The approach was then used in a sub-study of 1 196 NAFLD participants, which revealed that Type II Diabetes (T2D) and Coronary Heart Disease (CHD) was 2-3 times more prevalent in NAFLD participants with adverse muscle composition (upper left corner of figure) compared to other NAFLD participants demonstrating that muscle composition evaluated using MRI could be used to effectively assess sarcopenia-related complications.

These studies will be discussed in detail through an oral and poster presentation at The Liver Meeting® next month.


Oral Presentation:

On the Definition of Sarcopenia within NAFLD – Results from the large UK Biobank Imaging Study

Session: Parallel 35: NAFLD and NASH: Epidemiology and Outcomes
Date & Time: Monday, November 11, 2:00 pm
Location: Constitution Ballroom, Hynes Convention Center

Poster Presentation:

Adverse Muscle Composition within NAFLD is Associated with Increased Comorbidity – Results from the large UK Biobank Imaging Study  

Location: Hynes Convention Center, Hall B
Poster Sessions Date & Time
Saturday, November 9, 5:15 – 6:15 pm 

Attend AMRA’s presentations and connect with our team at AASLD’s The Liver Meeting® in November to learn more about our research and technology.

Access online abstracts on HEPATOLOGY


For further information, please contact:

Rosemary Shull
SVP Global Business Development & Marketing

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI. AMRA was founded in 2010 as a spin-off of Linköping University, Sweden, with the aim to support transformative care and vital decision-making from clinical research to health and wellness.


Marie Börjesson
Senior Director, Brand & Marketing


Latest News


Meet Us Here